The Ratio of C-Reactive Protein/Albumin is a Novel Inflammatory Predictor of Overall Survival in Cisplatin-Based Treated Patients with Metastatic Nasopharyngeal Carcinoma

Table 2

Univariate and multivariate analysis of OS in 148 patients with metastatic nasopharyngeal carcinoma.

Variable	Univariate		Multivariate
	value	HR (95% CI)	value	HR (95% CI)
Gender (male/female)	0.570	0.83 (0.435–1.581)
Age, years (<50/≥50)	0.773	1.078 (0.646–1.801)
KPS (≥90/<90)	0.411	0.765 (0.403–1.451)
Number of involved sites (one/multiple)	0.179	1.369 (0.866–2.164)
Synchronous metastasis (yes/no)	0.168	0.704 (0.427–1.160)
Liver metastasis (yes/no)	0.802	0.942 (0.593–1.498)
Lung metastasis (yes/no)	0.389	1.219 (0.777–1.914)
Bone metastasis (yes/no)	0.071	1.525 (0.965–2.411)
Smoking (yes/no)	0.210	0.750 (0.478–1.177)
GPS (0/1/2)	<0.001	3.135 (2.309–4.256)	0.001	2.137 (1.369–3.337)
CRP/Alb (<0.189/≥0.189)	0.003	1.998 (1.253–3.185)	0.024	1.867 (1.085–3.210)
Serum LDH, U/L (<212/≥212)	0.006	1.880 (1.193–2.962)	0.602	0.858 (0.483–1.524)
EBV-DNA, copies/mL (<4.82 × 104/≥4.82 × 104)	<0.001	4.554 (2.792–7.427)	0.041	2.012 (1.027–3.941)
Chemotherapy regimen (PF/TP/TPF)	0.644	0.922 (0.653–1.302)
Treatment response (CR + PR/PD + SD)	0.005	1.984 (1.231–3.197)	0.420	1.242 (0.734–2.101)
NLR (<5/≥5)	0.017	2.039 (1.133–3.671)	0.192	1.522 (0.810–2.858)
PLR (<152/≥152)	0.002	2.450 (1.407–4.267)	0.128	1.617 (0.870–3.003)
Hemoglobin, g/L (<11/≥11)	0.585	1.172 (0.664–2.069)

CRP/Alb: C-reactive protein/albumin ratio; KPS: Karnofsky Performance Score; GPS: Glasgow Prognostic Score; NLR: neutrophil to lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; LDH: lactate dehydrogenase; .